SLU-PP-332 is an experimental small molecule designed as a potent ERR (estrogen-related receptor) agonist. By targeting ERR pathways,
it has shown potential to enhance mitochondrial activity, energy expenditure, and endurance capacity. While still under preclinical
investigation, SLU-PP-332 represents a promising therapeutic candidate for metabolic health and performance.
Key Benefits
• Mitochondrial Support: Enhances oxidative metabolism and energy efficiency.
• Improved Endurance: Preclinical studies suggest greater exercise tolerance and stamina.
• Metabolic Enhancement: May promote fat utilization and glucose regulation.
• Research Tool: Valuable for exploring novel ERR-targeted therapies.
Clinical Findings
• Preclinical animal studies show increased aerobic capacity and mitochondrial biogenesis.
• Early research indicates potential applications in metabolic disorders and performance enhancement.
• No human clinical data yet available — ongoing evaluation in laboratory research.
Safety & Tolerability
• Safety data currently limited to preclinical models.
• No established adverse event profile in humans.
• Further investigation required before clinical translation.
For research and informational purposes only – not for medical use.



Reviews
There are no reviews yet.